A prospective study of frequency and characteristics of cough during ACE inhibitor treatment

References

• The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension (JSH2014). Hypertens Res 2014;37:253–387
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure; results of the cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429–35
   PubMed Web of Science ®Google Scholar
• The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye L, et al., on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669–77
   PubMed Web of Science ®Google Scholar
• The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;32:821–8
   Google Scholar
• Kober L, Torp-Pedersen C, Carlsen JE, et al., for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670–6
   PubMed Web of Science ®Google Scholar
• The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease. Randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 2003;362:782–8
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033–41
   PubMed Web of Science ®Google Scholar
• Beckett N, Peters R, Fletcher AE, et al, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or old. N Engl J Med 2008;358:1887–98
   PubMed Web of Science ®Google Scholar
• Maschio G, Alberti D, Locatelli F, et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE inhibition in progressive renal insufficiency (AIPRI) study. J Cardiovasc Pharmacol 1999;33:S16–20
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Pema A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359–64
   PubMed Web of Science ®Google Scholar
• Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828–31
   PubMed Web of Science ®Google Scholar
• Van Vark LC, Bertrand M, Martijn Akkerhuis K, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012;33:2088–97
   PubMed Web of Science ®Google Scholar
• Savarese G, Costanzo P, George J, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013;61:131–42
   PubMed Web of Science ®Google Scholar
• Dezsi CA. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a clinical review of the evidence. Am J Cardiovasc Drugs 2014;14:167–73
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014;174:773–85
   PubMed Web of Science ®Google Scholar
• HOPE/HOPE-TOO study investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005;112:1339–46
   PubMed Web of Science ®Google Scholar
• Buch P, Rasmussen S, Abildstrom SZ, et al. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur Heart J 2005;26:145–52
   PubMed Web of Science ®Google Scholar
• Visser LE, Stricker BH, van der Velden J, et al. Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study. J Clin Epidemiol 1995;48:851–7
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med 2010;123:1016–130
   PubMed Web of Science ®Google Scholar
• Saruta T, Arakawa K, Iimura O, et al. Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate. Hypertens Res 1999;22:197–202
   PubMed Web of Science ®Google Scholar
• Sadanaga T, Yoshimura M, Sakamoto T, et al. Enalapril-induced cough is associated with non-severe heart failure. Int J Cardiol 2009;135:275–6
   PubMed Web of Science ®Google Scholar
• Sato A, Fukuda S. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens 2010;24:387–94
   PubMed Web of Science ®Google Scholar
• Franova S. The influence of inhaled furosemide on adverse effects of ACE-inhibitors in airway. Bratisl Lek Listy 2001;102:309–13
   PubMedGoogle Scholar
• Franova S, Nosalova G, Antosova M, Nosal S. Enalapril and diltiazem co-administration and respiratory side effects of enalapril. Physiol Res 2005;54:515–20
   PubMed Web of Science ®Google Scholar
• Visser LE, Vlug AE, van der Lei J, Stricker BH. Cough due to ACE inhibitors: a case-control study using automated general practice data. Eur J Clin Pharmacol 1996;49:439–44
   PubMed Web of Science ®Google Scholar
• Mooraki A, Jenabi A, Jabbari M, et al. Noscapine suppresses angiotensin converting enzyme inhibitor-induced cough. Nephrology 2005;10:348–50
   PubMed Web of Science ®Google Scholar
• Hirata R, Nabe T, Kohno S. Augmentation of spontaneous cough by enalapril through up-regulation of bradykinin B1 receptors in guinea pigs. Eur J Pharmacol 2003;474:255–60
   PubMed Web of Science ®Google Scholar
• Fox AJ, Lalloo UG, Belvisi MG, et al. Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med 1996;2:814–17
   PubMed Web of Science ®Google Scholar
• Mukae S, Itoh S, Aoki S, et al. Association of polymorphisms of the renin–angiotensin system and bradykinin B2 receptor with ACE-inihibitor-related cough. J Hum Hypertens 2002;16:857–63
   PubMed Web of Science ®Google Scholar
• Nishio K, Kashiki S, Tachibana H, Kobayashi Y. Angiotensin-converting enzyme and bradykinin gene polymorphisms and cough: a meta-analysis. World J Cardiol 2011;26:329–36
   Google Scholar
• Takahashi T, Yamaguchi E, Furuya K, Kawakami Y. The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage. Respir Med 2001;95:130–5
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Munakata M, Yamaguchi E, et al. Molecular studies of bronchial asthma, sarcoidosis and angiotensin converting enzyme inhibitor-induced cough. Respirology 1998;3:45–9
   PubMedGoogle Scholar
• Okamura H, Nishimura E, Kariya S, et al. No relation between angiotensin-converting enzyme (ACE) inhibitor-induced cough and ACE gene polymorphism, plasma bradykinin, substance P and ACE inhibitor concentration in Japanese patients. Yakugaku Zasshi 2001;121:253–7
   PubMed Web of Science ®Google Scholar
• Woo SW, Bang S, Chung MW, et al. Lack of association between ACE and bradykinin B2 receptor gene polymorphisms and ACE inhibitor-induced coughing in hypertensive Koreans. J Clin Pharm Ther 2009;34:561–7
   PubMed Web of Science ®Google Scholar
• Mahmoudpour SH, Leusink M, van der Puten L, et al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacogenomics 2013;14:249–60
   PubMed Web of Science ®Google Scholar
• Arai T, Yoshimi N, Fujiwara H, Sekizawa K. Serum substance P concentrations and silent aspiration in elderly patients with stroke. Neurology 2003;61:1625–6
   PubMed Web of Science ®Google Scholar
• Subissi A, Guelfi M, Criscuoli M. Angiotensin converting enzyme inhibitors potentiate the bronchoconstriction induced by substance P in the guinea-pig. Br J Pharmacol 1990;100:502–6
   PubMed Web of Science ®Google Scholar
• Tomaki M, Ichinose M, Miura M, et al. Angiotensin converting enzyme (ACE) inhibitor-induced cough and substance P. Thorax 1996;51:199–201
   PubMed Web of Science ®Google Scholar
• Goto N, Shirahase M, Hatta H, et al. Influence of type of questionnaire on the prevalence of coughing in patients taking angiotensin converting enzyme inhibitors (ACEI). Jpn J Clin Pharmacol Ther 1996;27:725–30
   Google Scholar
• Dashti-Khvidaki S, Faghihi T, Ahmadi F, Khalili H. Cough induced by losartan with resolution after substitution with enalapril. Clin Ther 2008;30:548–51
   PubMed Web of Science ®Google Scholar
• Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol 1999;47:111–14
   PubMed Web of Science ®Google Scholar
• Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf 1996;15:72–8
   PubMed Web of Science ®Google Scholar
• Reisin L, Schneeweiss A. Complete spontaneous remission of cough induced by ACE inhibitors during chronic therapy in hypertensive patients. J Hum Hypertens 1992;6:333–5
   PubMed Web of Science ®Google Scholar
• Reisin L, Schneeweiss A. Spontaneous disappearance of cough induced by angiotensin-converting enzyme inhibitors (captopril or enalapril). Am J Cardiol 1992;70:398–9
   PubMed Web of Science ®Google Scholar
• Yeo WW, Maclean D, Richardson PJ, Ramsay LE. Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double-blind condition. Br J Clin Pharmacol 1991;31:356–9
   PubMed Web of Science ®Google Scholar
• Sunaga K, Fujimura A, Shiga T, Ebihara A. Chronopharmacology of enalapril in hypertensive patients. Eur J Clin Pharmacol 1995;48:441–5
   PubMed Web of Science ®Google Scholar
• Tumanan-Mendoza BA, Dans AL, Villacin LL, et al. Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is. J Clin Epidemiol 2007;60:547–53
   Google Scholar
• Takahama K, Araki T, Fuchikami J, et al. Studies of the magnitude and the mechanism of cough potentiation by angiotensin-converting enzyme inhibitors in guinea-pigs: involvement of bradykinin in the potentiation. J Pharm Pharmacol 1996;48:1027–33
   PubMed Web of Science ®Google Scholar
• Shionoiri H, Takasaki I, Minamisawa K, et al. Cough-challenge trial with a new angiotensin-converting enzyme inhibitor, imidapril. J Clin Pharmacol 1998;38:442–6
   PubMed Web of Science ®Google Scholar
• Israili ZH, Hall WD. Cough and angioneurotic dema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992;117:234–42
   PubMed Web of Science ®Google Scholar
• Dicpinigaitia PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129:169S–73S
   PubMed Web of Science ®Google Scholar